Radium-223 has reduced the risk of death by 30.5% in castration-resistant prostate cancer patients with symptomatic bone metastases and no known visceral metastatic disease
Bayer HealthCare has announced that the New England Journal of Medicine ( NEJM ) has published results from Phase III ALSYMPCA study of Radium 223 dichloride ( Alpharadin; 223-Ra; Radium-223 ). In summary: a) significant overall survival benefit has been observed with Radium 223 in patients who received prior treatment with Docetaxel ( Taxotere ) and in those who did not; b) Radium 223 has significantly delayed time to first symptomatic skeletal event; c) all main secondary efficacy endpoints with Radium 223 were met, showing clinical benefit with Radium 223 in patients with castration-resistant prostate cancer ( CRPC ) and symptomatic bone metastases.
The ALSYMPCA ( ALpharadin in SYMptomatic Prostate CAncer ) trial was a phase III, randomized, double-blind, placebo-controlled international study of Radium 223 dichloride versus placebo in patients with CRPC, symptomatic bone metastases and no known visceral metastatic disease.
The trial enrolled 921 patients in more than 100 Centers in 19 countries. Patients were stratified based on whether or not they had received Docetaxel prior to study enrollment. The study treatment consisted of best standard of care and up to six intravenous injections of Radium 223 or placebo each separated by an interval of four weeks.
The primary endpoint of the study was overall survival. A key secondary endpoint was time to first symptomatic skeletal event. Symptomatic skeletal event was defined as first use of external beam radiation therapy to relieve skeletal pain, new symptomatic pathologic bone fracture, occurrence of spinal cord compression or tumour-related orthopedic surgical intervention.
The overall survival impact of Radium 223 was consistent in both patients who received treatment with Docetaxel prior to study enrollment and in those patients who did not receive prior Docetaxel treatment.
In the interim analysis, Radium 223 reduced the risk of death by 25% ( hazard ratio, HR=0.755 ) compared to placebo in patients who received prior Docetaxel treatment and by 39% ( HR=0.611 ) compared with placebo in those who did not.
In the updated analysis, Radium 223 reduced the risk of death by 29% ( HR=0.710 ) compared with placebo in those who were given prior Docetaxel and by 26% ( HR=0.745 ) compared with placebo in those who were not.
Radium 223 significantly improved overall survival in the overall study population at the interim analysis ( HR=0.695, p=0.00185 ); median overall survival was 14 months with Radium 223 plus best standard of care vs 11.2 months with placebo plus best standard of care.
These findings were supported by the updated analysis in which Radium 223 showed the same significant improvement in overall survival ( HR=0.695; median overall surival was 14.9 vs 11.3 months ).
The main secondary endpoints in the ALSYMPCA trial has provided further support for the efficacy of Radium 223. In the interim analysis, Radium 223 significantly prolonged the time to the first symptomatic skeletal event compared with placebo ( median 15.6 months vs 9.8 months, respectively; HR=0.658, p less than 0.001 ).
In addition, Radium 223 has significantly delayed the time to alkaline phosphatase ( ALP ) progression ( HR=0.167, p less than 0.00001 ) and time to prostate-specific antigen ( PSA ) progression ( HR=0.643, p less than 0.00001 ). These are two important biomarkers for CRPC with bone metastases; ALP is a marker that indicates bone health, and PSA is a marker often used to track prostate cancer disease progression. Similar results were observed in the updated analysis.
The number of patients experiencing adverse events was lower in the Radium 223 group compared with the placebo group ( 93% vs 96% ). Most adverse events associated with Radium 223 were mild to moderate. The most common adverse drug events ( greater than or equal to 10% ) in patients receiving Radium 223 were diarrhea, nausea, vomiting and thrombocytopenia. Grade 3 and 4 treatment-emergent adverse events were reported among 56.5% of Radium 223-treated patients and 62.5% of placebo-treated patients. The most common hematologic laboratory abnormalities ( greater than or equal to 5% ) were anemia, thrombocytopenia and neutropenia.
Radium 223 is an alpha particle-emitting radioactive therapeutic agent with an anti-tumour effect on bone metastases. The active ingredient is the alpha particle-emitting isotope Radium-223, which mimics calcium and forms complexes with the bone mineral hydroxyapatite at areas of increased bone turnover, such as bone metastases.
The high linear energy transfer of radium 223 may cause double-strand DNA breaks in adjacent cells, resulting in an anti-tumour effect on bone metastases. The alpha particle range from Radium 223 is less than 100 micrometers, which may limit damage to the surrounding normal tissues.
Radium 223 is approved in the United States and is marketed under the brand name Xofigo for the treatment of patients with CRPC, symptomatic bone metastases and no known visceral metastatic disease.
Prostate cancer is the most common non-cutaneous malignancy in men worldwide. A majority of men with CRPC have radiological evidence of bone metastases. Once the cancer cells settle in the bone, they interfere with bone strength, often leading to pain, fracture and other complications that can significantly impair a mans health. Bone metastases secondary to prostate cancer typically target the lumbar spine, vertebrae and pelvis. In fact, bone metastases are the main cause of morbidity and death in patients with CRPC.
Source: Bayer, 2013